Please assess the completion status of the following clinical trial:

Trial Title: Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal information~* Eastern Cooperative Oncology Group (ECOG) =\< 2~* In vitro dasatinib sensitivity (IC 50 =\< 50 nm per MTS assay)~* Diagnosis of CLL and must meet one of the following:~  * Relapsed CLL in all patients who have failed at least one prior treatment, regardless of risk group~ * OR De novo (treatment-naïve) patients age \>= 65 who are not candidates for or do not want to pursue aggressive chemotherapy treatment~* Have indications for treatment or evidence of progressive disease defined as follows (1996 NCI working group):~  * Massive or progressive splenomegaly~ * Massive lymph nodes (\>= 10 cm), nodal clusters (\>= 10 cm), or progressive lymphadenopathy~ * Symptomatic anemia and/or thrombocytopenia (Rai stages III or IV disease)~ * Autoimmune hemolytic anemia and/or thrombocytopenia that are poorly responsive to corticosteroid therapy~ * Progressive lymphocytosis with increase in lymphocyte count of \>= 50% over a 2-month period or an anticipated doubling time of \< 6 months~ * Repeated episodes of infection~* Have not received CLL treatment within the past 2 weeks~* Total bilirubin \< 2.0 x upper limit of normal (ULN)~* Aspartate aminotransferase (AST) =\< 2.5 x ULN~* Alanine aminotransferase (ALT) =\< 2.5 x ULN~* Serum creatinine \< 2.0 x ULN~* International normalized ratio (INR) =\< 1.2~* Platelet (Plt) count \> 30,000~* Ability to take oral medication (dasatinib must be swallowed whole)~* No clinically significant infections as determined by the investigator~* Normal corrected QT (QTc) interval (\< 450 msec)~* Serum potassium and magnesium are within normal limits~* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (sensitivity =\< 25 IU HCG/L) within 72 hours prior to the start of study drug administration~* Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped prior to study enrollment; women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy~* After consent, discontinuation (washout period) of any medications known to contribute significantly to the risk of QT prolongation or interfere with cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) mediated drug metabolism~* Patient agrees to discontinue St. John's Wort while receiving dasatinib therapy (discontinue St. John's Wort at least 5 days before starting dasatinib)~* Patient agrees that IV bisphosphonates will be withheld for the first eight weeks of dasatinib therapy due to risk of hypocalcemia~* Patient agrees to discontinue anti-coagulants and anti-platelet drugs; note: a low dose aspirin regimen (81mg QD) is permitted with close monitoring of the subject's platelets for a level \>= 50,000/mm\^3~Exclusion Criteria:~* Patients may not receive concurrent chemotherapy, radiotherapy, or immunotherapy~* Pleural or pericardial effusion of any grade~* Uncontrolled angina, \> New York Heart Association (NYHA) class III congestive heart failure or myocardial infarction (MI) within 6 months prior to study enrollment~* Diagnosed congenital long QT syndrome~* Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)~* Prolonged QTc interval on pre-entry electrocardiogram (\> 450 msec)~* Subjects who are detained or imprisoned are not eligible~* History of significant bleeding disorder unrelated to cancer, including:~  * Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)~ * Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)~* May not take concomitant medications that are generally accepted to have a risk of causing Torsades de Pointes including: (patients must discontinue drug 7 days prior to starting dasatinib)~  * Quinidine, procainamide, disopyramide~ * Amiodarone, sotalol, ibutilide, dofetilide~ * Erythromycin, clarithromycin~ * Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide~ * Cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, sparfloxacin, lidoflazine~* Patients already taking other CYP inducers or inhibitors other than those listed above are eligible for the study only after principal investigator (PI) review; dose adjustments and/or monitoring of drug levels where applicable will be made as needed by the PI after consultation with pharmacy~* Women who:~  * Are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 weeks after cessation of study drug, or~ * Have a positive pregnancy test at baseline, or~ * Are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (dasatinib) (Type: EXPERIMENTAL): Patients receive dasatinib PO QD during course 1 and if tolerated, BID in subsequent courses. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete